KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Receivables - Other (2022 - 2025)

Historic Receivables - Other for NovoCure (NVCR) over the last 4 years, with Q3 2025 value amounting to $7.2 million.

  • NovoCure's Receivables - Other rose 2614.9% to $7.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.2 million, marking a year-over-year increase of 2614.9%. This contributed to the annual value of $5.7 million for FY2024, which is 3467.42% up from last year.
  • As of Q3 2025, NovoCure's Receivables - Other stood at $7.2 million, which was up 2614.9% from $6.9 million recorded in Q2 2025.
  • NovoCure's Receivables - Other's 5-year high stood at $7.2 million during Q3 2025, with a 5-year trough of $2.2 million in Q4 2022.
  • Its 4-year average for Receivables - Other is $5.4 million, with a median of $5.7 million in 2024.
  • As far as peak fluctuations go, NovoCure's Receivables - Other skyrocketed by 9393.25% in 2023, and later soared by 2614.9% in 2025.
  • NovoCure's Receivables - Other (Quarter) stood at $2.2 million in 2022, then skyrocketed by 93.93% to $4.3 million in 2023, then skyrocketed by 34.67% to $5.7 million in 2024, then grew by 26.57% to $7.2 million in 2025.
  • Its last three reported values are $7.2 million in Q3 2025, $6.9 million for Q2 2025, and $6.6 million during Q1 2025.